Schlegel A, Schwab R B, Scherer P E, Lisanti M P
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
J Biol Chem. 1999 Aug 6;274(32):22660-7. doi: 10.1074/jbc.274.32.22660.
Here, we have created a series of caveolin-1 (Cav-1) deletion mutants to examine whether the membrane spanning segment is required for membrane attachment of caveolin-1 in vivo. One mutant, Cav-1-(1-101), contains only the cytoplasmic N-terminal domain and lacks the membrane spanning domain and the C-terminal domain. Interestingly, Cav-1-(1-101) still behaves as an integral membrane protein but lacks any known signals for lipid modification. In striking contrast, another deletion mutant, Cav-1-(1-81), behaved as a soluble protein. These results implicate caveolin-1 residues 82-101 (also known as the caveolin scaffolding domain) in membrane attachment. In accordance with the postulated role of the caveolin-1 scaffolding domain as an inhibitor of signal transduction, Cav-1-(1-101) retained the ability to functionally inhibit signaling along the p42/44 mitogen-activated protein kinase cascade, whereas Cav-1-(1-81) was completely ineffective. To rule out the possibility that membrane attachment mediated by the caveolin scaffolding domain was indirect, we reconstituted the membrane binding of caveolin-1 in vitro. By using purified glutathione S-transferase-caveolin-1 fusion proteins and reconstituted lipid vesicles, we show that the caveolin-1 scaffolding domain and the C-terminal domain (residues 135-178) are both sufficient for membrane attachment in vitro. However, the putative membrane spanning domain (residues 102-134) did not show any physical association with membranes in this in vitro system. Taken together, our results provide strong evidence that the caveolin scaffolding domain contributes to the membrane attachment of caveolin-1.
在此,我们构建了一系列小窝蛋白-1(Cav-1)缺失突变体,以研究跨膜区段对于小窝蛋白-1在体内与膜附着是否必需。一个突变体Cav-1-(1-101)仅包含胞质N端结构域,缺少跨膜结构域和C端结构域。有趣的是,Cav-1-(1-101)仍表现为整合膜蛋白,但缺乏任何已知的脂质修饰信号。与之形成鲜明对比的是,另一个缺失突变体Cav-1-(1-81)表现为可溶性蛋白。这些结果表明小窝蛋白-1的82-101位残基(也称为小窝蛋白支架结构域)参与膜附着。根据小窝蛋白-1支架结构域作为信号转导抑制剂的假定作用,Cav-1-(1-101)保留了沿p42/44丝裂原活化蛋白激酶级联反应在功能上抑制信号传导的能力,而Cav-1-(1-81)则完全无效。为排除小窝蛋白支架结构域介导的膜附着是间接的这种可能性,我们在体外重建了小窝蛋白-1的膜结合。通过使用纯化的谷胱甘肽S-转移酶-小窝蛋白-1融合蛋白和重建的脂质囊泡,我们表明小窝蛋白-1支架结构域和C端结构域(135-178位残基)在体外均足以实现膜附着。然而,在这个体外系统中,假定的跨膜结构域(102-134位残基)未显示出与膜有任何物理关联。综上所述,我们的结果提供了有力证据,证明小窝蛋白支架结构域有助于小窝蛋白-1与膜的附着。